ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,741 to 3,760 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
EZ/Simva 10/40 mg vs Placebo: Percutaneous Coronary Intervention (PCI)8 of 944

17 of 929

-1.0 points

-2.1 to 0.1

1,873NCT00092677

An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)

EZ/Simva 10/40 mg vs Placebo: Coronary Artery Bypass Grafting (CABG)69 of 944

100 of 929

-3.5 points

-6.1 to -0.9

1,873NCT00092677

An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)

EZ/Simva 10/40 mg vs Placebo: Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of ICE (Ischemic Cardiovascular Events)148 of 944

187 of 929

-4.5 points

-7.9 to -1.0

1,873NCT00092677

An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)

EZ/Simva 10/40 mg vs Placebo: Death Due to Cancer39 of 944

23 of 929

1.7 points

0.0 to 3.3

1,873NCT00092677

An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)

EZ/Simva 10/40 mg vs Placebo: Aortic Valve Replacement (AVR)267 of 944

278 of 929

-1.6 points

-5.7 to 2.5

1,873NCT00092677

An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)

EZ/Simva 10/40 mg vs Placebo: Nonfatal Myocardial Infarction (MI)17 of 944

26 of 929

-1.0 points

-2.4 to 0.4

1,873NCT00092677

An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)

EZ/Simva 10/40 mg vs Placebo: Cardiovascular Death47 of 944

56 of 929

-1.0 points

-3.2 to 1.0

1,873NCT00092677

An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)

EZ/Simva 10/40 mg vs Placebo: Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of AVE (Aortic Valve Events)308 of 944

326 of 929

-2.5 points

-6.7 to 1.8

1,873NCT00092677

An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)

EZ/Simva 10/40 mg vs Placebo: Congestive Heart Failure (CHF) Due to Progression of Aortic Stenosis (AS)25 of 944

23 of 929

0.2 points

-1.3 to 1.7

1,873NCT00092677

An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)

EZ/Simva 10/40 mg vs Placebo: Nonhemorrhagic Stroke33 of 944

29 of 929

0.4 points

-1.3 to 2.0

1,873NCT00092677

An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)

EZ/Simva 10/40 mg vs Placebo: Incident Cancer105 of 943

70 of 929

3.6 points

1.0 to 6.3

1,872NCT00092677

An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)

Mirabegron 50 mg vs Solifenacin 5 mg: serious adverse events14 of 936

13 of 934

0.1 points

-1.0 to 1.3

1,870NCT01638000

A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.

Prospective Group vs Retrospective Arm: Wound Infection After Open Heart Surgery4 of 272

17 of 1,597

0.4 points

-0.7 to 2.7

1,869NCT02020018

Negative Pressure Wound Therapy for Prevention of Poststernotomy Infection

EVO100 Gel vs Placebo Gel: serious adverse events4 of 926

9 of 937

-0.5 points

-1.4 to 0.3

1,863NCT04553068

Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection

Ticagrelor In-Hosp vs Ticagrelor Pre-Hosp: serious adverse events143 of 950

140 of 908

-0.4 points

-3.6 to 2.9

1,858NCT01347580

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)

Spiriva Respimat + Striverdi Respimat vs Spiriva 18 mcg + Striverdi Respimat: serious adverse events30 of 1,298

12 of 560

0.2 points

-1.5 to 1.5

1,858NCT02173769

Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy

Cocoa Extract vs Cocoa Extract Placebo: Incident Mild Cognitive Impairment47 of 916

63 of 940

-1.6 points

-3.7 to 0.6

1,856NCT03035201

COcoa Supplement and Multivitamin Outcomes Study for the Mind

Multivitamin vs Multivitamin Placebo: Incidence of Mild Cognitive Impairment Among Those Free at Baseline53 of 920

57 of 936

-0.3 points

-2.5 to 1.8

1,856NCT03035201

COcoa Supplement and Multivitamin Outcomes Study for the Mind

Genotype-Guided Therapy vs Conventional Therapy: Occurrence of the a Major Adverse Cardiovascular Event in Subjects Identified as CPY2C19 LOF Carriers by TaqMan.35 of 903

54 of 946

-1.8 points

-3.8 to 0.1

1,849NCT01742117

Tailored Antiplatelet Therapy Following PCI

Genotype-Guided Therapy vs Conventional Therapy: Thrombolysis in Myocardial Infarction Major or Minor Bleeding in Subjects Identified as CPY2C19 LOF Carriers by TaqMan.16 of 903

14 of 946

0.3 points

-0.9 to 1.5

1,849NCT01742117

Tailored Antiplatelet Therapy Following PCI

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=188"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=188

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00092677-6e8c9d3b",
        "title": "EZ/Simva 10/40 mg vs Placebo: Percutaneous Coronary Intervention (PCI)",
        "summary": "8 of 944 against 17 of 929; risk difference -1.0 points, 95% interval -2.1 to 0.1; NCT00092677, An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)",
        "record": "/library/comparisons/NCT00092677-6e8c9d3b",
        "nct_id": "NCT00092677",
        "kind": "outcome",
        "participants": 1873,
        "risk_difference": {
          "value": -0.0098246702304282,
          "lower": -0.021413042130547434,
          "upper": 0.0008237209434589169
        },
        "group_1": "8 of 944",
        "group_2": "17 of 929",
        "difference": "-1.0 points",
        "interval": "-2.1 to 0.1",
        "trial_title": "An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)"
      },
      {
        "id": "NCT00092677-95642c0a",
        "title": "EZ/Simva 10/40 mg vs Placebo: Coronary Artery Bypass Grafting (CABG)",
        "summary": "69 of 944 against 100 of 929; risk difference -3.5 points, 95% interval -6.1 to -0.9; NCT00092677, An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)",
        "record": "/library/comparisons/NCT00092677-95642c0a",
        "nct_id": "NCT00092677",
        "kind": "outcome",
        "participants": 1873,
        "risk_difference": {
          "value": -0.034549406141103065,
          "lower": -0.06078258675544725,
          "upper": -0.008577861012001597
        },
        "group_1": "69 of 944",
        "group_2": "100 of 929",
        "difference": "-3.5 points",
        "interval": "-6.1 to -0.9",
        "trial_title": "An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=189",
  "request_id": "o42TFfHE8hzF83NA"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?